Monday, Inhibrx Biosciences, Inc. (INBX) announced that the U.S. Food and Drug Administration has accepted for filing its Biologics License Application seeking approval of ozekibart for the treatment of patients with unresectable or metastatic conventional chondrosarcoma, a rare type of cancer.
The agency has assigned a Prescription Drug User Fee Act or PDUFA goal date of April 14, 2027.
If approved, ozekibart would become Inhibrx's first commercial product and the first systemic therapy ever approved for patients with unresectable or metastatic conventional chondrosarcoma.
The application was backed by positive results from the ChonDRAgon study, which met its primary endpoint of a statistically significant and clinically meaningful median progression-free survival in the patients.
During the randomized, blinded, placebo-controlled, registrational trial, ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo, more than doubling median progression-free survival to 5.52 months versus 2.66 months for placebo.
Currently, INBX is climbing 1.40 percent, to $93.49 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.